Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 11
2004 13
2005 14
2006 10
2007 10
2008 16
2009 9
2010 20
2011 17
2012 21
2013 10
2014 10
2015 10
2016 12
2017 12
2018 17
2019 15
2020 13
2021 18
2022 19
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

275 results

Results by year

Filters applied: . Clear all
Page 1
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2024 Mar 23:S0939-4753(24)00125-X. doi: 10.1016/j.numecd.2024.03.023. Online ahead of print. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
Validation in type 2 diabetes of a metabolomic signature of all-cause mortality.
Copetti M, Baroni MG, Buzzetti R, Cavallo MG, Cossu E, D'Angelo P, Cosmo S, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Savino AF, Trischitta V. Copetti M, et al. Among authors: d angelo p. Diabetes Metab Res Rev. 2024 Feb;40(2):e3734. doi: 10.1002/dmrr.3734. Epub 2023 Oct 15. Diabetes Metab Res Rev. 2024. PMID: 37839040
Full Spectroscopic Characterization of the Molecular Oxygen-Based Methane to Methanol Conversion over Open Fe(II) Sites in a Metal-Organic Framework.
Tofoni A, Tavani F, Vandone M, Braglia L, Borfecchia E, Ghigna P, Stoian DC, Grell T, Stolfi S, Colombo V, D'Angelo P. Tofoni A, et al. Among authors: d angelo p. J Am Chem Soc. 2023 Sep 27;145(38):21040-21052. doi: 10.1021/jacs.3c07216. Epub 2023 Sep 18. J Am Chem Soc. 2023. PMID: 37721732 Free PMC article.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Ding WY, Fawzy AM, Romiti GF, Proietti M, Pastori D, Huisman MV, Lip GYH; GLORIA-AF Investigators. Ding WY, et al. J Thromb Thrombolysis. 2024 Jan;57(1):39-49. doi: 10.1007/s11239-023-02866-y. Epub 2023 Aug 11. J Thromb Thrombolysis. 2024. PMID: 37566295 Free PMC article.
275 results